Professor Li Min (李敏教授) is an acclaimed scholar in the treatment of neurodegenerative diseases using Chinese medicine. She is a research scientist in the field of autophagy, Chinese medicinal pharmacology in treating and prevention of Parkinson’s disease (PD), Alzheimer's disease (AD) and Amyotrophic lateral sclerosis (ALS). Professor Li was  named the First National Outstanding Female Chinese Medicine Practitioner (全國首屆傑出女中醫師) in 2007 and has consistently been ranked among the world’s top 2% scientists by Stanford University in recent years.

Joining Hong Kong Baptist University (HKBU) in 2001, Professor Li currently holds several positions in the School of Chinese Medicine (SCM): Chair Professor of Chinese Medicine, Ma Pak Leung Endowed Professor in Innovative Neuromedicine, Programme Director of Bachelor of Chinese Medicine  & Bachelor of Science (Hons) in Biomedical Science, and also the Director of Mr. & Mrs. Ko Chi Ming Centre for Parkinson's Disease Research (CPDR) and Golden Meditech Centre for NeuroRegeneration Sciences (GCNS).  Professor Li officially succeeds Professor Lyu Aiping as the Dean of School of Chinese Medicine effective 1 April 2025. 

Professor Li obtained her bachelor’s degree in Chinese medicine from Henan University of Chinese Medicine in Zhengzhou, China, in 1985. She also earned a master’s degree in Chinese medicine from Guangzhou University of Chinese Medicine in Guangzhou, China, in 1988, and completed her PhD in Cardiology at the School of Medicine, Tokai University, Kanagawa, Japan, in 2001. Prof. Li joined the School of Chinese Medicine in Hong Kong Baptist University (HKBU) in 2001 as an Assistant Professor. She was promoted to Full Professor in 2014, appointed as the Endowed Professor in Innovative Neuromedicine in 2024, and became a Chair Professor in 2025.

Prof. Li's long-term research interests include:

• The relationship between autophagy regulation and neurodegenerative diseases such as Parkinson's Disease (PD), Alzheimer's Disease (AD), and Amyotrophic Lateral Sclerosis (ALS).
• The use of Traditional Chinese Medicine (TCM) for the prevention and treatment of neurodegenerative diseases.
• The development of molecular targets for new drug discovery from TCM for neurodegenerative diseases.

Prof. Li's current research directions focus on:

• Autophagy regulation in neurodegenerative diseases, including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS).
• Understanding the neuroprotective effects and underlying mechanisms of TCM on neurodegenerative diseases, including AD, PD, and ALS.
• Investigating the efficacy and safety of TCM in the treatment of neurodegenerative diseases, such as AD and PD, through randomized controlled clinical trials, as well as exploring the interaction between TCM and Western medicine.